DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,414 | -99.9% | 9,731 | -0.4% | 1.20% | +5.2% |
| Q2 2023 | $2,345,520 | -8.6% | 9,773 | -4.0% | 1.14% | -12.4% |
| Q1 2023 | $2,566,523 | +95309.8% | 10,183 | +0.5% | 1.30% | -7.5% |
| Q4 2022 | $2,690 | -99.9% | 10,133 | -1.5% | 1.40% | -2.5% |
| Q3 2022 | $2,656,000 | +1.0% | 10,283 | -0.9% | 1.44% | +4.4% |
| Q2 2022 | $2,630,000 | -16.1% | 10,373 | -3.0% | 1.38% | -2.5% |
| Q1 2022 | $3,136,000 | -14.1% | 10,690 | -3.6% | 1.42% | +5.4% |
| Q4 2021 | $3,649,000 | +4.4% | 11,090 | -3.4% | 1.34% | -1.0% |
| Q3 2021 | $3,494,000 | +4.9% | 11,477 | -7.5% | 1.36% | +3.2% |
| Q2 2021 | $3,331,000 | +12.3% | 12,412 | -5.8% | 1.31% | +3.5% |
| Q1 2021 | $2,967,000 | +0.4% | 13,182 | -0.9% | 1.27% | -7.6% |
| Q4 2020 | $2,954,000 | +0.8% | 13,296 | -2.3% | 1.37% | -14.9% |
| Q3 2020 | $2,932,000 | +9.3% | 13,614 | -10.3% | 1.61% | +5.6% |
| Q2 2020 | $2,682,000 | +21.9% | 15,169 | -4.6% | 1.53% | +1.4% |
| Q1 2020 | $2,201,000 | -11.5% | 15,904 | -1.8% | 1.51% | +7.6% |
| Q4 2019 | $2,486,000 | -7.2% | 16,199 | -12.6% | 1.40% | -11.2% |
| Q3 2019 | $2,678,000 | -10.7% | 18,539 | -11.7% | 1.58% | -12.1% |
| Q2 2019 | $3,000,000 | +2.7% | 20,989 | -5.1% | 1.79% | -1.9% |
| Q1 2019 | $2,921,000 | -99.9% | 22,124 | -0.2% | 1.83% | +12.6% |
| Q4 2018 | $2,286,583,000 | -5.7% | 22,174 | -0.7% | 1.62% | +15.8% |
| Q3 2018 | $2,425,726,000 | +11.0% | 22,324 | +0.8% | 1.40% | +5.3% |
| Q2 2018 | $2,186,058,000 | +0.9% | 22,153 | +0.1% | 1.33% | +3.6% |
| Q1 2018 | $2,166,552,000 | +4.8% | 22,128 | -0.6% | 1.28% | +1.3% |
| Q4 2017 | $2,067,009,000 | +6.0% | 22,269 | -2.0% | 1.27% | +9.7% |
| Q3 2017 | $1,949,694,000 | +0.4% | 22,729 | -1.2% | 1.16% | -1.8% |
| Q2 2017 | $1,941,645,000 | +1.3% | 23,008 | +2.6% | 1.18% | -0.2% |
| Q1 2017 | $1,917,326,000 | +15.5% | 22,417 | +5.1% | 1.18% | +6.1% |
| Q4 2016 | $1,659,549,000 | -0.1% | 21,320 | +0.6% | 1.11% | -2.9% |
| Q3 2016 | $1,661,868,000 | -19.0% | 21,200 | +4.4% | 1.14% | -22.7% |
| Q2 2016 | $2,051,310,000 | +7.6% | 20,310 | +1.0% | 1.48% | +0.9% |
| Q1 2016 | $1,907,160,000 | +1.0% | 20,105 | -1.1% | 1.47% | +0.1% |
| Q4 2015 | $1,888,250,000 | +10.9% | 20,330 | +1.8% | 1.47% | +6.7% |
| Q3 2015 | $1,702,496,000 | -0.3% | 19,980 | +0.2% | 1.37% | +8.1% |
| Q2 2015 | $1,707,093,000 | +0.8% | 19,945 | -0.0% | 1.27% | +2.3% |
| Q1 2015 | $1,693,755,000 | -4.5% | 19,950 | -3.6% | 1.24% | -3.7% |
| Q4 2014 | $1,774,197,000 | +10.7% | 20,700 | -1.8% | 1.29% | +7.5% |
| Q3 2014 | $1,602,418,000 | -4.3% | 21,090 | -0.8% | 1.20% | -1.2% |
| Q2 2014 | $1,674,193,000 | +3.9% | 21,265 | -1.0% | 1.21% | +2.7% |
| Q1 2014 | $1,611,375,000 | -3.0% | 21,485 | -0.1% | 1.18% | -3.4% |
| Q4 2013 | $1,660,572,000 | +10.4% | 21,510 | -0.9% | 1.22% | +3.9% |
| Q3 2013 | $1,504,591,000 | +7.3% | 21,705 | -2.0% | 1.18% | +0.8% |
| Q2 2013 | $1,401,779,000 | – | 22,145 | – | 1.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |